RyboDyn partners with U.S. Department of War to advance AI-discovered ADC therapies for Lung cancer

CAR-T Digest - August 2020

Weekly Digest - July 2026

09 July 2026: RyboDyn partners with U.S department of war to advance AI-discovered ADC therapies for Lung cancer

RyboDyn received a $1.3 million grant from the U.S. Department of War through the CDMRP Peer Reviewed Cancer Research Program to advance the preclinical development of two novel antibody-based therapies for lung cancer
The funding will support two therapeutic programs, an antibody-drug conjugate and a T-cell engager-that target two previously undiscovered cancer cell-surface proteins identified directly from patient tumors using RyboDyn’s AI-powered RyboCypher platform and CypherAtlas knowledgebase
RyboDyn’s discovery approach starts with patient tumors rather than known biological targets, enabling the identification of new, cancer-specific proteins that are absent from healthy tissues, which aims to improve the likelihood of developing safer and more effective first-in-class cancer therapies
Using its CypherAtlas database, which includes data from more than 2,000 patient samples across 12 cancer types, RyboDyn identified two highly prevalent lung cancer cell-surface targets. The grant will fund the generation of ADC and TCE candidates, biological characterization, and in vivo proof-of-concept studies for these programs
The project addresses an important unmet need in lung cancer, particularly among military service members and veterans who have an increased risk due to exposures such as burn pits, asbestos, diesel exhaust, and Agent Orange. The award also validates RyboDyn’s AI-driven target discovery platform and supports the expansion of its first-in-class oncology pipeline